Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent
The IFNL3 genotype predicts the clearance of hepatitis C virus (HCV), spontaneously and with interferon (IFN)-based therapy. The responder genotype is associated with lower expression of interferon stimulated genes (ISGs) in liver biopsies from chronic hepatitis C patients. However, ISGs represent m...
Saved in:
| Published in | Genes and immunity Vol. 15; no. 2; pp. 88 - 94 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
01.03.2014
Nature Publishing Group |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The IFNL3 genotype predicts the clearance of hepatitis C virus (HCV), spontaneously and with interferon (IFN)-based therapy. The responder genotype is associated with lower expression of interferon stimulated genes (ISGs) in liver biopsies from chronic hepatitis C patients. However, ISGs represent many interacting molecular pathways, and we hypothesised that the IFNL3 genotype may produce a characteristic pattern of ISG expression explaining the effect of genotype on viral clearance. For the first time, we identified an association between a cluster of ISGs, the metallothioneins (MTs) and IFNL3 genotype. Importantly, MTs were significantly upregulated (in contrast to most other ISGs) in HCV-infected liver biopsies of rs8099917 responders. An association between lower fibrosis scores and higher MT levels was demonstrated underlying clinical relevance of this association. As expected, overall ISGs were significantly downregulated in biopsies from subjects with the IFNL3 rs8099917 responder genotype (
P
=2.38 × 10
−7
). Peripheral blood analysis revealed paradoxical and not previously described findings with upregulation of ISGs seen in the responder genotype (
P
=1.00 × 10
−4
). The higher MT expression in responders may contribute to their improved viral clearance and MT-inducing agents may be useful adjuncts to therapy for HCV. Upregulation of immune cell ISGs in responders may also contribute to the IFNL3 genotype effect. |
|---|---|
| AbstractList | The IFNL3 genotype predicts the clearance of hepatitis C virus (HCV), spontaneously and with interferon (IFN)-based therapy. The responder genotype is associated with lower expression of interferon stimulated genes (ISGs) in liver biopsies from chronic hepatitis C patients. However, ISGs represent many interacting molecular pathways, and we hypothesised that the IFNL3 genotype may produce a characteristic pattern of ISG expression explaining the effect of genotype on viral clearance. For the first time, we identified an association between a cluster of ISGs, the metallothioneins (MTs) and IFNL3 genotype. Importantly, MTs were significantly upregulated (in contrast to most other ISGs) in HCV-infected liver biopsies of rs8099917 responders. An association between lower fibrosis scores and higher MT levels was demonstrated underlying clinical relevance of this association. As expected, overall ISGs were significantly downregulated in biopsies from subjects with the IFNL3 rs8099917 responder genotype (P=2.38 × 10−7). Peripheral blood analysis revealed paradoxical and not previously described findings with upregulation of ISGs seen in the responder genotype (P=1.00 × 10−4). The higher MT expression in responders may contribute to their improved viral clearance and MT-inducing agents may be useful adjuncts to therapy for HCV. Upregulation of immune cell ISGs in responders may also contribute to the IFNL3 genotype effect. The IFNL3 genotype predicts the clearance of hepatitis C virus (HCV), spontaneously and with interferon (IFN)-based therapy. The responder genotype is associated with lower expression of interferon stimulated genes (ISGs) in liver biopsies from chronic hepatitis C patients. However, ISGs represent many interacting molecular pathways, and we hypothesised that the IFNL3 genotype may produce a characteristic pattern of ISG expression explaining the effect of genotype on viral clearance. For the first time, we identified an association between a cluster of ISGs, the metallothioneins (MTs) and IFNL3 genotype. Importantly, MTs were significantly upregulated (in contrast to most other ISGs) in HCV-infected liver biopsies of rs8099917 responders. An association between lower fibrosis scores and higher MT levels was demonstrated underlying clinical relevance of this association. As expected, overall ISGs were significantly downregulated in biopsies from subjects with the IFNL3 rs8099917 responder genotype (P=2.38 × 10(-7)). Peripheral blood analysis revealed paradoxical and not previously described findings with upregulation of ISGs seen in the responder genotype (P=1.00 × 10(-4)). The higher MT expression in responders may contribute to their improved viral clearance and MT-inducing agents may be useful adjuncts to therapy for HCV. Upregulation of immune cell ISGs in responders may also contribute to the IFNL3 genotype effect. The IFNL3 genotype predicts the clearance of hepatitis C virus (HCV), spontaneously and with interferon (IFN)-based therapy. The responder genotype is associated with lower expression of interferon stimulated genes (ISGs) in liver biopsies from chronic hepatitis C patients. However, ISGs represent many interacting molecular pathways, and we hypothesised that the IFNL3 genotype may produce a characteristic pattern of ISG expression explaining the effect of genotype on viral clearance. For the first time, we identified an association between a cluster of ISGs, the metallothioneins (MTs) and IFNL3 genotype. Importantly, MTs were significantly upregulated (in contrast to most other ISGs) in HCV-infected liver biopsies of rs8099917 responders. An association between lower fibrosis scores and higher MT levels was demonstrated underlying clinical relevance of this association. As expected, overall ISGs were significantly downregulated in biopsies from subjects with the IFNL3 rs8099917 responder genotype (P = 2.38 x [10.sup.-7]). Peripheral blood analysis revealed paradoxical and not previously described findings with upregulation of ISGs seen in the responder genotype (P = 1.00 x [10.sup.-4]). The higher MTexpression in responders may contribute to their improved viral clearance and MT-inducing agents may be useful adjuncts to therapy for HCV. Upregulation of immune cell ISGs in responders may also contribute to the IFNL3 genotype effect. The IFNL3 genotype predicts the clearance of hepatitis C virus (HCV), spontaneously and with interferon (IFN)-based therapy. The responder genotype is associated with lower expression of interferon stimulated genes (ISGs) in liver biopsies from chronic hepatitis C patients. However, ISGs represent many interacting molecular pathways, and we hypothesised that the IFNL3 genotype may produce a characteristic pattern of ISG expression explaining the effect of genotype on viral clearance. For the first time, we identified an association between a cluster of ISGs, the metallothioneins (MTs) and IFNL3 genotype. Importantly, MTs were significantly upregulated (in contrast to most other ISGs) in HCV-infected liver biopsies of rs8099917 responders. An association between lower fibrosis scores and higher MT levels was demonstrated underlying clinical relevance of this association. As expected, overall ISGs were significantly downregulated in biopsies from subjects with the IFNL3 rs8099917 responder genotype (P=2.38 × 10(-7)). Peripheral blood analysis revealed paradoxical and not previously described findings with upregulation of ISGs seen in the responder genotype (P=1.00 × 10(-4)). The higher MT expression in responders may contribute to their improved viral clearance and MT-inducing agents may be useful adjuncts to therapy for HCV. Upregulation of immune cell ISGs in responders may also contribute to the IFNL3 genotype effect.The IFNL3 genotype predicts the clearance of hepatitis C virus (HCV), spontaneously and with interferon (IFN)-based therapy. The responder genotype is associated with lower expression of interferon stimulated genes (ISGs) in liver biopsies from chronic hepatitis C patients. However, ISGs represent many interacting molecular pathways, and we hypothesised that the IFNL3 genotype may produce a characteristic pattern of ISG expression explaining the effect of genotype on viral clearance. For the first time, we identified an association between a cluster of ISGs, the metallothioneins (MTs) and IFNL3 genotype. Importantly, MTs were significantly upregulated (in contrast to most other ISGs) in HCV-infected liver biopsies of rs8099917 responders. An association between lower fibrosis scores and higher MT levels was demonstrated underlying clinical relevance of this association. As expected, overall ISGs were significantly downregulated in biopsies from subjects with the IFNL3 rs8099917 responder genotype (P=2.38 × 10(-7)). Peripheral blood analysis revealed paradoxical and not previously described findings with upregulation of ISGs seen in the responder genotype (P=1.00 × 10(-4)). The higher MT expression in responders may contribute to their improved viral clearance and MT-inducing agents may be useful adjuncts to therapy for HCV. Upregulation of immune cell ISGs in responders may also contribute to the IFNL3 genotype effect. The IFNL3 genotype predicts the clearance of hepatitis C virus (HCV), spontaneously and with interferon (IFN)-based therapy. The responder genotype is associated with lower expression of interferon stimulated genes (ISGs) in liver biopsies from chronic hepatitis C patients. However, ISGs represent many interacting molecular pathways, and we hypothesised that the IFNL3 genotype may produce a characteristic pattern of ISG expression explaining the effect of genotype on viral clearance. For the first time, we identified an association between a cluster of ISGs, the metallothioneins (MTs) and IFNL3 genotype. Importantly, MTs were significantly upregulated (in contrast to most other ISGs) in HCV-infected liver biopsies of rs8099917 responders. An association between lower fibrosis scores and higher MT levels was demonstrated underlying clinical relevance of this association. As expected, overall ISGs were significantly downregulated in biopsies from subjects with the IFNL3 rs8099917 responder genotype (P=2.38 x 10 super(-7)). Peripheral blood analysis revealed paradoxical and not previously described findings with upregulation of ISGs seen in the responder genotype (P=1.00 x 10 super(-4)). The higher MT expression in responders may contribute to their improved viral clearance and MT-inducing agents may be useful adjuncts to therapy for HCV. Upregulation of immune cell ISGs in responders may also contribute to the IFNL3 genotype effect. The IFNL3 genotype predicts the clearance of hepatitis C virus (HCV), spontaneously and with interferon (IFN)-based therapy. The responder genotype is associated with lower expression of interferon stimulated genes (ISGs) in liver biopsies from chronic hepatitis C patients. However, ISGs represent many interacting molecular pathways, and we hypothesised that the IFNL3 genotype may produce a characteristic pattern of ISG expression explaining the effect of genotype on viral clearance. For the first time, we identified an association between a cluster of ISGs, the metallothioneins (MTs) and IFNL3 genotype. Importantly, MTs were significantly upregulated (in contrast to most other ISGs) in HCV-infected liver biopsies of rs8099917 responders. An association between lower fibrosis scores and higher MT levels was demonstrated underlying clinical relevance of this association. As expected, overall ISGs were significantly downregulated in biopsies from subjects with the IFNL3 rs8099917 responder genotype ( P =2.38 × 10 −7 ). Peripheral blood analysis revealed paradoxical and not previously described findings with upregulation of ISGs seen in the responder genotype ( P =1.00 × 10 −4 ). The higher MT expression in responders may contribute to their improved viral clearance and MT-inducing agents may be useful adjuncts to therapy for HCV. Upregulation of immune cell ISGs in responders may also contribute to the IFNL3 genotype effect. The IFNL3 genotype predicts the clearance of hepatitis C virus (HCV), spontaneously and with interferon (IFN)-based therapy. The responder genotype is associated with lower expression of interferon stimulated genes (ISGs) in liver biopsies from chronic hepatitis C patients. However, ISGs represent many interacting molecular pathways, and we hypothesised that the IFNL3 genotype may produce a characteristic pattern of ISG expression explaining the effect of genotype on viral clearance. For the first time, we identified an association between a cluster of ISGs, the metallothioneins (MTs) and IFNL3 genotype. Importantly, MTs were significantly upregulated (in contrast to most other ISGs) in HCV-infected liver biopsies of rs8099917 responders. An association between lower fibrosis scores and higher MT levels was demonstrated underlying clinical relevance of this association. As expected, overall ISGs were significantly downregulated in biopsies from subjects with the IFNL3 rs8099917 responder genotype (P = 2.38 x [10.sup.-7]). Peripheral blood analysis revealed paradoxical and not previously described findings with upregulation of ISGs seen in the responder genotype (P = 1.00 x [10.sup.-4]). The higher MTexpression in responders may contribute to their improved viral clearance and MT-inducing agents may be useful adjuncts to therapy for HCV. Upregulation of immune cell ISGs in responders may also contribute to the IFNL3 genotype effect. Genes and Immunity (2014) 15, 88-94; doi: 10.1038/gene.2013.66; published online 16 January 2014 Keywords: IFNL3; metallothioneins; hepatitis C virus; interferon-stimulated genes |
| Audience | Academic |
| Author | Stewart, G J Ahlenstiel, G Douglas, M W Booth, D R Yang, J YH Parnell, G Patrick, E George, J O'Connor, K S Suppiah, V Read, S A van der Poorten, D Liddle, C Leung, R |
| Author_xml | – sequence: 1 givenname: K S surname: O'Connor fullname: O'Connor, K S email: koco2654@uni.sydney.edu.au organization: Institute for Immunology and Allergy Research, Westmead Millennium Institute, University of Sydney – sequence: 2 givenname: G surname: Parnell fullname: Parnell, G organization: Institute for Immunology and Allergy Research, Westmead Millennium Institute, University of Sydney – sequence: 3 givenname: E surname: Patrick fullname: Patrick, E organization: Department of Mathematics, University of Sydney – sequence: 4 givenname: G surname: Ahlenstiel fullname: Ahlenstiel, G organization: Storr Liver Unit, Westmead Millennium Institute and Westmead Hospital, University of Sydney – sequence: 5 givenname: V surname: Suppiah fullname: Suppiah, V organization: Institute for Immunology and Allergy Research, Westmead Millennium Institute, University of Sydney, Storr Liver Unit, Westmead Millennium Institute and Westmead Hospital, University of Sydney – sequence: 6 givenname: D surname: van der Poorten fullname: van der Poorten, D organization: Storr Liver Unit, Westmead Millennium Institute and Westmead Hospital, University of Sydney – sequence: 7 givenname: S A surname: Read fullname: Read, S A organization: Storr Liver Unit, Westmead Millennium Institute and Westmead Hospital, University of Sydney, Centre for Infectious Diseases and Microbiology, Sydney Emerging infections and Biosecurity Institute, University of Sydney and Westmead Hospital – sequence: 8 givenname: R surname: Leung fullname: Leung, R organization: Institute for Immunology and Allergy Research, Westmead Millennium Institute, University of Sydney, Storr Liver Unit, Westmead Millennium Institute and Westmead Hospital, University of Sydney – sequence: 9 givenname: M W surname: Douglas fullname: Douglas, M W organization: Storr Liver Unit, Westmead Millennium Institute and Westmead Hospital, University of Sydney, Centre for Infectious Diseases and Microbiology, Sydney Emerging infections and Biosecurity Institute, University of Sydney and Westmead Hospital – sequence: 10 givenname: J YH surname: Yang fullname: Yang, J YH organization: Department of Mathematics, University of Sydney – sequence: 11 givenname: G J surname: Stewart fullname: Stewart, G J organization: Institute for Immunology and Allergy Research, Westmead Millennium Institute, University of Sydney – sequence: 12 givenname: C surname: Liddle fullname: Liddle, C organization: Storr Liver Unit, Westmead Millennium Institute and Westmead Hospital, University of Sydney – sequence: 13 givenname: J surname: George fullname: George, J organization: Storr Liver Unit, Westmead Millennium Institute and Westmead Hospital, University of Sydney – sequence: 14 givenname: D R surname: Booth fullname: Booth, D R organization: Institute for Immunology and Allergy Research, Westmead Millennium Institute, University of Sydney |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24335707$$D View this record in MEDLINE/PubMed |
| BookMark | eNqN0luL1DAUAOAgK-5F33yWgi8Kdsw97eMyuO7AoODlOaTp6UyWTlqTVHb_venOLjrLKlJom_Q7pyfJOUVHfvCA0EuCFwSz6v0GPCwoJmwh5RN0QriSpeAKH83vUpa8UvUxOo3xCmMiiayfoWPKGRMKqxMElzCa5Gyxg2T6fkhbl9M7X8D1GCDGPCryyG7D4LPa3urkYrEsfrowxfyxA5tuWSxWF5_WrMgVDelmhLKFEXwLPj1HTzvTR3hx9zxD3y8-fFteluvPH1fL83VpBalT2VSmkQ2TprNNbTmzUmFimsY0qu4EpaTLd0N4WzFlKZakwcJyzPNM11US2Bl6s887huHHBDHpnYsW-t54GKaoiaCck1oI9R8UCypkRatMXz-gV8MUfF6IppITxWRF5L9UzsUFrWlFfquN6UHnzRtSMHb-tT5nkgulFMdZLR5R-Wph52w-oM7l-YOAtwcB2SS4ThszxahXX78c2ld3hU7NDlo9Brcz4UbfN0UGdA9sGGIM0GnrkpnPOFfhek2wnjtPz52n587Tcl7-uwdB93n_wss9j5n5DYQ_dusx_wsqSuXY |
| CitedBy_id | crossref_primary_10_3389_fimmu_2021_699722 crossref_primary_10_3389_fimmu_2021_739918 crossref_primary_10_1371_journal_pone_0136227 crossref_primary_10_1371_journal_ppat_1008778 crossref_primary_10_1002_elps_201500345 crossref_primary_10_1007_s12011_017_1061_8 crossref_primary_10_1177_0300985815588607 crossref_primary_10_1007_s12011_018_1369_z crossref_primary_10_1039_d0mt00220h crossref_primary_10_1111_jvh_12845 crossref_primary_10_3390_ijms18102197 crossref_primary_10_1002_jmv_27721 crossref_primary_10_1007_s00705_020_04901_2 crossref_primary_10_1016_j_cmrp_2018_10_002 crossref_primary_10_1016_j_chemosphere_2016_04_018 crossref_primary_10_1038_ncomms15245 crossref_primary_10_1093_advances_nmz013 crossref_primary_10_1089_jir_2018_0175 |
| Cites_doi | 10.1073/pnas.0707882105 10.1002/hep.25647 10.1002/hep.24678 10.1053/j.gastro.2010.11.039 10.1038/ni873 10.1002/hep.20371 10.1038/ni875 10.1038/314637a0 10.1371/journal.pone.0037998 10.1385/BTER:75:1-3:53 10.1016/j.jhep.2011.09.008 10.1093/jn/130.5.1085 10.1053/j.gastro.2012.01.028 10.1093/carcin/bgs287 10.1038/gene.2009.72 10.1128/MCB.01808-08 10.1186/gm273 10.1155/2005/262597 10.1136/gut.2007.128611 10.1053/j.gastro.2010.04.049 10.1186/gb-2010-11-10-r106 10.1002/hep.1840360704 10.1038/ng.447 10.1111/j.1365-2893.2012.01610.x 10.1002/hep.25582 10.1128/JVI.73.6.4713-4720.1999 10.1186/gb-2009-10-3-r25 10.1073/pnas.1211776110 10.1055/s-2000-9505 10.1097/MEG.0b013e32833caf7b 10.1128/MCB.6.1.26 10.1038/ng.449 10.1002/hep.510310316 10.1006/taap.1996.8054 10.1046/j.1524-475X.2002.20101.x 10.1016/j.proghi.2008.10.002 10.3109/03602532.2012.725414 10.1053/j.gastro.2006.09.052 10.1073/pnas.83.10.3346 10.1186/1756-8722-5-41 10.1073/pnas.250477397 10.1038/nature09907 10.1016/j.mrfmmm.2003.07.013 10.1053/gast.2002.1232082 10.1002/hep.23912 10.2174/138955707781024490 10.1038/nature08463 10.1046/j.1365-2893.2001.00311.x 10.1038/nature08309 |
| ContentType | Journal Article |
| Copyright | Macmillan Publishers Limited 2014 COPYRIGHT 2014 Nature Publishing Group Copyright Nature Publishing Group Mar 2014 Macmillan Publishers Limited 2014. |
| Copyright_xml | – notice: Macmillan Publishers Limited 2014 – notice: COPYRIGHT 2014 Nature Publishing Group – notice: Copyright Nature Publishing Group Mar 2014 – notice: Macmillan Publishers Limited 2014. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7T5 7X7 7XB 88A 88E 8AO 8C1 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS RC3 7X8 7U9 |
| DOI | 10.1038/gene.2013.66 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts ProQuest SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Proquest Medical Database Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts MEDLINE - Academic Virology and AIDS Abstracts |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Genetics Abstracts Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic Virology and AIDS Abstracts |
| DatabaseTitleList | ProQuest Central Student MEDLINE ProQuest Central Student MEDLINE - Academic Genetics Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1476-5470 |
| EndPage | 94 |
| ExternalDocumentID | 3237720951 A364577740 24335707 10_1038_gene_2013_66 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Australia New South Wales Australia |
| GeographicLocations_xml | – name: New South Wales Australia – name: Australia |
| GroupedDBID | --- -Q- 0R~ 29H 2WC 36B 39C 4.4 406 53G 5GY 5RE 70F 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8R4 8R5 AACDK AANZL AASML AATNV AAYZH ABAKF ABAWZ ABBRH ABDBE ABDBF ABFSG ABJNI ABLJU ABRTQ ABUWG ABZZP ACAOD ACGFS ACKTT ACPRK ACRQY ACSTC ACUHS ACZOJ ADBBV AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AEZWR AFBBN AFDZB AFHIU AFKRA AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AHWEU AIGIU AILAN AIXLP AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF ATHPR AXYYD AYFIA B0M BAWUL BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CAG CCPQU COF CS3 DIK DNIVK DPUIP DU5 E3Z EAD EAP EBC EBD EBLON EBS EE. EIOEI EJD EMB EMK EMOBN EPL ESX F5P FDQFY FERAY FIGPU FIZPM FSGXE FYUFA HCIFZ HMCUK HZ~ IAO IHR INH INR ISR ITC IWAJR JSO JZLTJ KQ8 LK8 M1P M7P NQJWS O9- OK1 OVD P2P PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q2X RNS RNT RNTTT ROL SNX SNYQT SOHCF SOJ SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TEORI TR2 TSG TUS UKHRP Y6R ~8M AAYXX CITATION CGR CUY CVF ECM EIF NPM AEIIB PMFND 3V. 7T5 7XB 88A 8FD 8FK AZQEC DWQXO FR3 GNUQQ H94 K9. P64 PKEHL PQEST PQUKI PRINS RC3 7X8 7U9 |
| ID | FETCH-LOGICAL-c519t-b8ab6b36afcb9c43c6701abbab79f5221ff52a14d837c2061b05c40414dff86e3 |
| IEDL.DBID | 7X7 |
| ISSN | 1466-4879 1476-5470 |
| IngestDate | Wed Jul 30 10:28:11 EDT 2025 Fri Jul 11 14:01:30 EDT 2025 Sat Aug 23 12:44:51 EDT 2025 Fri Jul 25 09:06:53 EDT 2025 Tue Jun 17 21:45:00 EDT 2025 Tue Jun 10 20:10:34 EDT 2025 Fri Jun 27 04:33:20 EDT 2025 Thu Apr 03 07:04:44 EDT 2025 Tue Jul 01 05:06:27 EDT 2025 Thu Apr 24 23:08:38 EDT 2025 Mon Jul 21 06:08:38 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | hepatitis C virus metallothioneins interferon-stimulated genes IFNL3 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c519t-b8ab6b36afcb9c43c6701abbab79f5221ff52a14d837c2061b05c40414dff86e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 24335707 |
| PQID | 1504529281 |
| PQPubID | 42724 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_1524419557 proquest_miscellaneous_1505256828 proquest_journals_2641736816 proquest_journals_1504529281 gale_infotracmisc_A364577740 gale_infotracacademiconefile_A364577740 gale_incontextgauss_ISR_A364577740 pubmed_primary_24335707 crossref_citationtrail_10_1038_gene_2013_66 crossref_primary_10_1038_gene_2013_66 springer_journals_10_1038_gene_2013_66 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-03-01 |
| PublicationDateYYYYMMDD | 2014-03-01 |
| PublicationDate_xml | – month: 03 year: 2014 text: 2014-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England – name: Hamilton |
| PublicationTitle | Genes and immunity |
| PublicationTitleAbbrev | Genes Immun |
| PublicationTitleAlternate | Genes Immun |
| PublicationYear | 2014 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | WuCPotCApetohLThalhamerTZhuBMurugaiyanGMetallothioneins negatively regulate IL-27-induced type 1 regulatory T-cell differentiationProc Natl Acad Sci USA2013110780278071:CAS:528:DC%2BC3sXptFWqsb4%3D10.1073/pnas.1211776110 Sarasin-FilipowiczMOakeleyEJDuongFHChristenVTerraccianoLFilipowiczWInterferon signaling and treatment outcome in chronic hepatitis CProc Natl Acad Sci USA2008105703470391:CAS:528:DC%2BD1cXmt1Ghurw%3D10.1073/pnas.0707882105 PedersenMOLarsenAStoltenbergMPenkowaMCell death in the injured brain: roles of metallothioneinsProg Histochem Cytochem2009441271:CAS:528:DC%2BD1MXlvVWjtbo%3D10.1016/j.proghi.2008.10.002 UrbanTJThompsonAJBradrickSSFellayJSchuppanDCroninKDIL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis CHepatology201052188818961:CAS:528:DC%2BC3cXhs1WltLvN10.1002/hep.23912 Ge D. http://compute1.lsrc.duke.edu/softwares/MetaP/metap.php . accessed: July 2013. NaggieSOsinusiAKatsounasALempickiRHerrmannEThompsonAJDysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic responseHepatology2012564444541:CAS:528:DC%2BC38XhtVylu7vL10.1002/hep.25647 TaiDITsaiSLChenYMChuangYLPengCYSheenISActivation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesisHepatology2000316566641:CAS:528:DC%2BD3cXhvFGjsr0%3D10.1002/hep.510310316 KohliAZhangXYangJRussellRSDonnellyRPSheikhFDistinct and overlapping genomic profiles and antiviral effects of Interferon-lambda and -alpha on HCV-infected and noninfected hepatoma cellsJ Viral Hepat2012198438531:STN:280:DC%2BC3s7gsVWmsA%3D%3D10.1111/j.1365-2893.2012.01610.x VarshneyUJahroudiNFosterRGedamuLStructure, organization, and regulation of human metallothionein IF gene: differential and cell-type-specific expression in response to heavy metals and glucocorticoidsMol Cell Biol1986626371:CAS:528:DyaL28XhtVegtbg%3D10.1128/MCB.6.1.26 CarreraGPaternainJLCarrereNFolchJCourtade-SaidiMOrfilaCHepatic metallothionein in patients with chronic hepatitis C: relationship with severity of liver disease and response to treatmentAm J Gastroenterol200398114211491:CAS:528:DC%2BD3sXksVent7g%3D12809840 TakahashiSMolecular functions of metallothionein and its role in hematological malignanciesJ Hematol Oncol20125411:CAS:528:DC%2BC38Xhslyitr3J10.1186/1756-8722-5-41 SmithKRSuppiahVO'ConnorKBergTWeltmanMAbateMLIdentification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohortGenome Med20113571:CAS:528:DC%2BC3MXht1Gis7zL10.1186/gm273 LansdownABMetallothioneins: potential therapeutic aids for wound healing in the skinWound Repair Regen20021013013210.1046/j.1524-475X.2002.20101.x AschnerMCherianMGKlaassenCDPalmiterRDEricksonJCBushAIMetallothioneins in brain—the role in physiology and pathologyToxicol Appl Pharmacol19971422292421:CAS:528:DyaK2sXhsFaqtrw%3D10.1006/taap.1996.8054 AndersSHuberWDifferential expression analysis for sequence count dataGenome Biol201011R1061:CAS:528:DC%2BC3cXhsVahs7bI10.1186/gb-2010-11-10-r106 KotenkoSVGallagherGBaurinVVLewis-AntesAShenMShahNKIFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complexNat Immunol2003469771:CAS:528:DC%2BD38Xps1eltL8%3D10.1038/ni875 FischerJBohmSScholzMMullerTWittHGeorgeJCombined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infectionHepatology201255170017101:CAS:528:DC%2BC38XnsFOrtbg%3D10.1002/hep.25582 AsselahTDe MuynckSBroetPMasliah-PlanchonJBlanluetMBiecheIIL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis CJ Hepatol2012565275321:CAS:528:DC%2BC38XislSqurY%3D10.1016/j.jhep.2011.09.008 AlterHJSeeffLBRecovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcomeSemin Liver Dis20002017351:STN:280:DC%2BD3M%2Fit12ltA%3D%3D10.1055/s-2000-9505 NagamineTSuzukiKKondoTNakazatoKKakizakiSTakagiHInterferon-alpha-induced changes in metallothionein expression in liver biopsies from patients with chronic hepatitis CCan J Gastroenterol20051948148610.1155/2005/262597 HondaMSakaiAYamashitaTNakamotoYMizukoshiESakaiYHepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis CGastroenterology20101394995091:CAS:528:DC%2BC3cXpsVGnu7Y%3D10.1053/j.gastro.2010.04.049 SchmidtCJHamerDHCell specificity and an effect of ras on human metallothionein gene expressionProc Natl Acad Sci USA198683334633501:CAS:528:DyaL28XktF2ksbw%3D10.1073/pnas.83.10.3346 KrizkovaSRyvolovaMHrabetaJAdamVStiborovaMEckschlagerTMetallothioneins and zinc in cancer diagnosis and therapyDrug Metab Rev2012442873011:CAS:528:DC%2BC38XhvVSqu7jN10.3109/03602532.2012.725414 HoofnagleJHCourse and outcome of hepatitis CHepatology200236S21S2912407573 BochudPYBibertSKutalikZPatinEGuergnonJNalpasBIL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypesHepatology2012553843941:CAS:528:DC%2BC38Xht1yqu7s%3D10.1002/hep.24678 SchogginsJWWilsonSJPanisMMurphyMYJonesCTBieniaszPA diverse range of gene products are effectors of the type I interferon antiviral responseNature20114724814851:CAS:528:DC%2BC3MXksFWgur0%3D10.1038/nature09907 CherianMGJayasuryaABayBHMetallothioneins in human tumors and potential roles in carcinogenesisMutat Res20035332012091:CAS:528:DC%2BD3sXpt1eru70%3D10.1016/j.mrfmmm.2003.07.013 ThompsonAJClarkPJZhuMZhuQGeDSulkowskiMSGenome-wide association study identifies IL28B polymorphism to be associated with baseline ALT and hepatic necro-inflammatory activity in chronic hepatitis C patients enrolled in the IDEAL studyHepatology2010521220A1221A McGilvrayIFeldJJChenLPattulloVGuindiMFischerSHepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotypeGastroenterology2012142112211311:CAS:528:DC%2BC38Xjs1Wgur0%3D10.1053/j.gastro.2012.01.028 WitteKGruetzGVolkHDLoomanACAsadullahKSterryWDespite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokinesGenes Immun2009107027141:CAS:528:DC%2BD1MXhsV2ks7rP10.1038/gene.2009.72 YangCHMurtiAPfefferSRBasuLKimJGPfefferLMIFNalpha/beta promotes cell survival by activating NF-kappa BProc Natl Acad Sci USA20009713631136361:CAS:528:DC%2BD3cXoslygurc%3D10.1073/pnas.250477397 DavisSRCousinsRJMetallothionein expression in animals: a physiological perspective on functionJ Nutr2000130108510881:CAS:528:DC%2BD3cXivFKnt7o%3D10.1093/jn/130.5.1085 NagamineTTakagiHTakayamaHKojimaAKakizakiSMoriMPreliminary study of combination therapy with interferon-alpha and zinc in chronic hepatitis C patients with genotype 1bBiol Trace Elem Res20007553631:CAS:528:DC%2BD3cXlt1aiu74%3D10.1385/BTER:75:1-3:53 TakagiHNagamineTAbeTTakayamaHSatoKOtsukaTZinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis CJ Viral Hepat200183673711:STN:280:DC%2BD3Mrhs1Cltw%3D%3D10.1046/j.1365-2893.2001.00311.x GeDFellayJThompsonAJSimonJSShiannaKVUrbanTJGenetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature20094613994011:CAS:528:DC%2BD1MXpvFCrtbw%3D10.1038/nature08309 TanakaYNishidaNSugiyamaMKurosakiMMatsuuraKSakamotoNGenome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis CNat Genet200941110511091:CAS:528:DC%2BD1MXhtFaju73K10.1038/ng.449 DillMTDuongFHVogtJEBibertSBochudPYTerraccianoLInterferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis CGastroenterology2011140102110311:CAS:528:DC%2BC3MXjs1Wksrk%3D10.1053/j.gastro.2010.11.039 MoragaIHarariDSchreiberGUzeGPellegriniSReceptor density is key to the alpha2/beta interferon differential activitiesMol Cell Biol200929477847871:CAS:528:DC%2BD1MXhtFWgs73P10.1128/MCB.01808-08 ThomasDLThioCLMartinMPQiYGeDO'HuiginCGenetic variation in IL28B and spontaneous clearance of hepatitis C virusNature20094617988011:CAS:528:DC%2BD1MXhtFentb%2FJ10.1038/nature08463 MaoJYuHWangCSunLJiangWZhangPMetallothionein MT1M is a tumor suppressor of human hepatocellular carcinomasCarcinogenesis201233256825771:CAS:528:DC%2BC38XhslKrtrnE10.1093/carcin/bgs287 GirardSVossmanEMisekDEPodevinPHanashSBrechotCHepatitis C virus NS5A-regulated gene expression and signaling revealed via microarray and comparative promoter analysesHepatology2004407087181:CAS:528:DC%2BD2cXot1Ortb8%3D10.1002/hep.20371 AgundezJAGarcia-MartinEMaestroMLCuencaFMartinezCOrtegaLRelation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver diseasePloS One20127e379981:CAS:528:DC%2BC38Xot12rsr0%3D10.1371/journal.pone.0037998 LangmeadBTrapnellCPopMSalzbergSLUltrafast and memory-efficient alignment of short DNA sequences to the human genomeGenome Biol200910R2510.1186/gb-2009-10-3-r25 SuppiahVMoldovanMAhlenstielGBergTWeltmanMAbateMLIL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapyNat Genet200941110011041:CAS:528:DC%2BD1MXhtFaju7%2FM10.1038/ng.447 DevittELawlessMWSadlierDBrowneJAWalshCCroweJEarly viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24 hEur J Gastroenterol Hepatol201022121112201:CAS:528:DC%2BC3cXhtFaqsbzL10.1097/MEG.0b013e32833caf7b FriedmanRLStarkGRAlpha-Interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequencesNature19853146376391:CAS:528:DyaL2MXktVWnu7g%3D10.1038/314637a0 National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 J Mao (BFgene201366_CR33) 2012; 33 K Witte (BFgene201366_CR16) 2009; 10 I Moraga (BFgene201366_CR17) 2009; 29 T Marcello (BFgene201366_CR9) 2006; 131 AJ Thompson (BFgene201366_CR39) 2010; 52 L Chen (BFgene201366_CR20) 2010; 138 S Anders (BFgene201366_CR53) 2010; 11 U Varshney (BFgene201366_CR26) 1986; 6 JW Schoggins (BFgene201366_CR50) 2011; 472 P Sheppard (BFgene201366_CR8) 2003; 4 T Nagamine (BFgene201366_CR43) 2000; 75 BFgene201366_CR1 RL Friedman (BFgene201366_CR25) 1985; 314 G Carrera (BFgene201366_CR41) 2003; 98 A Kohli (BFgene201366_CR15) 2012; 19 AB Lansdown (BFgene201366_CR47) 2002; 10 JH Hoofnagle (BFgene201366_CR2) 2002; 36 S Krizkova (BFgene201366_CR29) 2012; 44 MT Dill (BFgene201366_CR12) 2011; 140 PY Bochud (BFgene201366_CR38) 2012; 55 SV Kotenko (BFgene201366_CR7) 2003; 4 TJ Urban (BFgene201366_CR14) 2010; 52 M Aschner (BFgene201366_CR49) 1997; 142 MG Cherian (BFgene201366_CR24) 2003; 533 JA Agundez (BFgene201366_CR37) 2012; 7 CJ Schmidt (BFgene201366_CR27) 1986; 83 CH Yang (BFgene201366_CR40) 2000; 97 E Devitt (BFgene201366_CR45) 2010; 22 S Naggie (BFgene201366_CR22) 2012; 56 B Langmead (BFgene201366_CR51) 2009; 10 X Li (BFgene201366_CR46) 2007; 7 C Wu (BFgene201366_CR30) 2013; 110 T Asselah (BFgene201366_CR6) 2012; 56 S Takahashi (BFgene201366_CR28) 2012; 5 DI Tai (BFgene201366_CR35) 2000; 31 DL Thomas (BFgene201366_CR23) 2009; 461 MO Pedersen (BFgene201366_CR48) 2009; 44 KR Smith (BFgene201366_CR18) 2011; 3 T Nagamine (BFgene201366_CR42) 2005; 19 T Asselah (BFgene201366_CR10) 2008; 57 BFgene201366_CR52 M Sarasin-Filipowicz (BFgene201366_CR11) 2008; 105 SR Davis (BFgene201366_CR31) 2000; 130 M Honda (BFgene201366_CR13) 2010; 139 H Takagi (BFgene201366_CR44) 2001; 8 V Suppiah (BFgene201366_CR4) 2009; 41 S Girard (BFgene201366_CR36) 2004; 40 H Marusawa (BFgene201366_CR34) 1999; 73 J Fischer (BFgene201366_CR19) 2012; 55 I McGilvray (BFgene201366_CR21) 2012; 142 Y Tanaka (BFgene201366_CR5) 2009; 41 D Ge (BFgene201366_CR3) 2009; 461 HJ Alter (BFgene201366_CR32) 2000; 20 |
| References_xml | – reference: TakahashiSMolecular functions of metallothionein and its role in hematological malignanciesJ Hematol Oncol20125411:CAS:528:DC%2BC38Xhslyitr3J10.1186/1756-8722-5-41 – reference: KrizkovaSRyvolovaMHrabetaJAdamVStiborovaMEckschlagerTMetallothioneins and zinc in cancer diagnosis and therapyDrug Metab Rev2012442873011:CAS:528:DC%2BC38XhvVSqu7jN10.3109/03602532.2012.725414 – reference: SuppiahVMoldovanMAhlenstielGBergTWeltmanMAbateMLIL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapyNat Genet200941110011041:CAS:528:DC%2BD1MXhtFaju7%2FM10.1038/ng.447 – reference: LangmeadBTrapnellCPopMSalzbergSLUltrafast and memory-efficient alignment of short DNA sequences to the human genomeGenome Biol200910R2510.1186/gb-2009-10-3-r25 – reference: MoragaIHarariDSchreiberGUzeGPellegriniSReceptor density is key to the alpha2/beta interferon differential activitiesMol Cell Biol200929477847871:CAS:528:DC%2BD1MXhtFWgs73P10.1128/MCB.01808-08 – reference: PedersenMOLarsenAStoltenbergMPenkowaMCell death in the injured brain: roles of metallothioneinsProg Histochem Cytochem2009441271:CAS:528:DC%2BD1MXlvVWjtbo%3D10.1016/j.proghi.2008.10.002 – reference: KohliAZhangXYangJRussellRSDonnellyRPSheikhFDistinct and overlapping genomic profiles and antiviral effects of Interferon-lambda and -alpha on HCV-infected and noninfected hepatoma cellsJ Viral Hepat2012198438531:STN:280:DC%2BC3s7gsVWmsA%3D%3D10.1111/j.1365-2893.2012.01610.x – reference: NaggieSOsinusiAKatsounasALempickiRHerrmannEThompsonAJDysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic responseHepatology2012564444541:CAS:528:DC%2BC38XhtVylu7vL10.1002/hep.25647 – reference: AgundezJAGarcia-MartinEMaestroMLCuencaFMartinezCOrtegaLRelation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver diseasePloS One20127e379981:CAS:528:DC%2BC38Xot12rsr0%3D10.1371/journal.pone.0037998 – reference: AsselahTDe MuynckSBroetPMasliah-PlanchonJBlanluetMBiecheIIL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis CJ Hepatol2012565275321:CAS:528:DC%2BC38XislSqurY%3D10.1016/j.jhep.2011.09.008 – reference: AndersSHuberWDifferential expression analysis for sequence count dataGenome Biol201011R1061:CAS:528:DC%2BC3cXhsVahs7bI10.1186/gb-2010-11-10-r106 – reference: ThomasDLThioCLMartinMPQiYGeDO'HuiginCGenetic variation in IL28B and spontaneous clearance of hepatitis C virusNature20094617988011:CAS:528:DC%2BD1MXhtFentb%2FJ10.1038/nature08463 – reference: AlterHJSeeffLBRecovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcomeSemin Liver Dis20002017351:STN:280:DC%2BD3M%2Fit12ltA%3D%3D10.1055/s-2000-9505 – reference: McGilvrayIFeldJJChenLPattulloVGuindiMFischerSHepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotypeGastroenterology2012142112211311:CAS:528:DC%2BC38Xjs1Wgur0%3D10.1053/j.gastro.2012.01.028 – reference: GeDFellayJThompsonAJSimonJSShiannaKVUrbanTJGenetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature20094613994011:CAS:528:DC%2BD1MXpvFCrtbw%3D10.1038/nature08309 – reference: NagamineTTakagiHTakayamaHKojimaAKakizakiSMoriMPreliminary study of combination therapy with interferon-alpha and zinc in chronic hepatitis C patients with genotype 1bBiol Trace Elem Res20007553631:CAS:528:DC%2BD3cXlt1aiu74%3D10.1385/BTER:75:1-3:53 – reference: GirardSVossmanEMisekDEPodevinPHanashSBrechotCHepatitis C virus NS5A-regulated gene expression and signaling revealed via microarray and comparative promoter analysesHepatology2004407087181:CAS:528:DC%2BD2cXot1Ortb8%3D10.1002/hep.20371 – reference: SchogginsJWWilsonSJPanisMMurphyMYJonesCTBieniaszPA diverse range of gene products are effectors of the type I interferon antiviral responseNature20114724814851:CAS:528:DC%2BC3MXksFWgur0%3D10.1038/nature09907 – reference: WuCPotCApetohLThalhamerTZhuBMurugaiyanGMetallothioneins negatively regulate IL-27-induced type 1 regulatory T-cell differentiationProc Natl Acad Sci USA2013110780278071:CAS:528:DC%2BC3sXptFWqsb4%3D10.1073/pnas.1211776110 – reference: BochudPYBibertSKutalikZPatinEGuergnonJNalpasBIL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypesHepatology2012553843941:CAS:528:DC%2BC38Xht1yqu7s%3D10.1002/hep.24678 – reference: SheppardPKindsvogelWXuWHendersonKSchlutsmeyerSWhitmoreTEIL-28, IL-29 and their class II cytokine receptor IL-28RNat Immunol2003463681:CAS:528:DC%2BD38Xps1elt7c%3D10.1038/ni873 – reference: SmithKRSuppiahVO'ConnorKBergTWeltmanMAbateMLIdentification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohortGenome Med20113571:CAS:528:DC%2BC3MXht1Gis7zL10.1186/gm273 – reference: AschnerMCherianMGKlaassenCDPalmiterRDEricksonJCBushAIMetallothioneins in brain—the role in physiology and pathologyToxicol Appl Pharmacol19971422292421:CAS:528:DyaK2sXhsFaqtrw%3D10.1006/taap.1996.8054 – reference: CherianMGJayasuryaABayBHMetallothioneins in human tumors and potential roles in carcinogenesisMutat Res20035332012091:CAS:528:DC%2BD3sXpt1eru70%3D10.1016/j.mrfmmm.2003.07.013 – reference: MarusawaHHijikataMChibaTShimotohnoKHepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activationJ Virol199973471347201:CAS:528:DyaK1MXjtFert7s%3D10233931112513 – reference: AsselahTBiecheINarguetSSabbaghALaurendeauIRipaultMPLiver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis CGut2008575165241:CAS:528:DC%2BD1cXltVKntbk%3D10.1136/gut.2007.128611 – reference: National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002; 123: 2082–2099. – reference: MaoJYuHWangCSunLJiangWZhangPMetallothionein MT1M is a tumor suppressor of human hepatocellular carcinomasCarcinogenesis201233256825771:CAS:528:DC%2BC38XhslKrtrnE10.1093/carcin/bgs287 – reference: LiXCaiLFengWDiabetes and metallothioneinMini Rev Med Chem200777617681:CAS:528:DC%2BD2sXmsFemtLw%3D10.2174/138955707781024490 – reference: NagamineTSuzukiKKondoTNakazatoKKakizakiSTakagiHInterferon-alpha-induced changes in metallothionein expression in liver biopsies from patients with chronic hepatitis CCan J Gastroenterol20051948148610.1155/2005/262597 – reference: SchmidtCJHamerDHCell specificity and an effect of ras on human metallothionein gene expressionProc Natl Acad Sci USA198683334633501:CAS:528:DyaL28XktF2ksbw%3D10.1073/pnas.83.10.3346 – reference: ThompsonAJClarkPJZhuMZhuQGeDSulkowskiMSGenome-wide association study identifies IL28B polymorphism to be associated with baseline ALT and hepatic necro-inflammatory activity in chronic hepatitis C patients enrolled in the IDEAL studyHepatology2010521220A1221A – reference: LansdownABMetallothioneins: potential therapeutic aids for wound healing in the skinWound Repair Regen20021013013210.1046/j.1524-475X.2002.20101.x – reference: DevittELawlessMWSadlierDBrowneJAWalshCCroweJEarly viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24 hEur J Gastroenterol Hepatol201022121112201:CAS:528:DC%2BC3cXhtFaqsbzL10.1097/MEG.0b013e32833caf7b – reference: HondaMSakaiAYamashitaTNakamotoYMizukoshiESakaiYHepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis CGastroenterology20101394995091:CAS:528:DC%2BC3cXpsVGnu7Y%3D10.1053/j.gastro.2010.04.049 – reference: FriedmanRLStarkGRAlpha-Interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequencesNature19853146376391:CAS:528:DyaL2MXktVWnu7g%3D10.1038/314637a0 – reference: TakagiHNagamineTAbeTTakayamaHSatoKOtsukaTZinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis CJ Viral Hepat200183673711:STN:280:DC%2BD3Mrhs1Cltw%3D%3D10.1046/j.1365-2893.2001.00311.x – reference: WitteKGruetzGVolkHDLoomanACAsadullahKSterryWDespite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokinesGenes Immun2009107027141:CAS:528:DC%2BD1MXhsV2ks7rP10.1038/gene.2009.72 – reference: HoofnagleJHCourse and outcome of hepatitis CHepatology200236S21S2912407573 – reference: UrbanTJThompsonAJBradrickSSFellayJSchuppanDCroninKDIL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis CHepatology201052188818961:CAS:528:DC%2BC3cXhs1WltLvN10.1002/hep.23912 – reference: VarshneyUJahroudiNFosterRGedamuLStructure, organization, and regulation of human metallothionein IF gene: differential and cell-type-specific expression in response to heavy metals and glucocorticoidsMol Cell Biol1986626371:CAS:528:DyaL28XhtVegtbg%3D10.1128/MCB.6.1.26 – reference: TaiDITsaiSLChenYMChuangYLPengCYSheenISActivation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesisHepatology2000316566641:CAS:528:DC%2BD3cXhvFGjsr0%3D10.1002/hep.510310316 – reference: Ge D. http://compute1.lsrc.duke.edu/softwares/MetaP/metap.php . accessed: July 2013. – reference: DavisSRCousinsRJMetallothionein expression in animals: a physiological perspective on functionJ Nutr2000130108510881:CAS:528:DC%2BD3cXivFKnt7o%3D10.1093/jn/130.5.1085 – reference: MarcelloTGrakouiABarba-SpaethGMachlinESKotenkoSVMacDonaldMRInterferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kineticsGastroenterology20061311887189810.1053/j.gastro.2006.09.052 – reference: DillMTDuongFHVogtJEBibertSBochudPYTerraccianoLInterferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis CGastroenterology2011140102110311:CAS:528:DC%2BC3MXjs1Wksrk%3D10.1053/j.gastro.2010.11.039 – reference: FischerJBohmSScholzMMullerTWittHGeorgeJCombined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infectionHepatology201255170017101:CAS:528:DC%2BC38XnsFOrtbg%3D10.1002/hep.25582 – reference: Sarasin-FilipowiczMOakeleyEJDuongFHChristenVTerraccianoLFilipowiczWInterferon signaling and treatment outcome in chronic hepatitis CProc Natl Acad Sci USA2008105703470391:CAS:528:DC%2BD1cXmt1Ghurw%3D10.1073/pnas.0707882105 – reference: KotenkoSVGallagherGBaurinVVLewis-AntesAShenMShahNKIFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complexNat Immunol2003469771:CAS:528:DC%2BD38Xps1eltL8%3D10.1038/ni875 – reference: CarreraGPaternainJLCarrereNFolchJCourtade-SaidiMOrfilaCHepatic metallothionein in patients with chronic hepatitis C: relationship with severity of liver disease and response to treatmentAm J Gastroenterol200398114211491:CAS:528:DC%2BD3sXksVent7g%3D12809840 – reference: ChenLBorozanISunJGuindiMFischerSFeldJCell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infectionGastroenterology2010138e1121e1123 – reference: YangCHMurtiAPfefferSRBasuLKimJGPfefferLMIFNalpha/beta promotes cell survival by activating NF-kappa BProc Natl Acad Sci USA20009713631136361:CAS:528:DC%2BD3cXoslygurc%3D10.1073/pnas.250477397 – reference: TanakaYNishidaNSugiyamaMKurosakiMMatsuuraKSakamotoNGenome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis CNat Genet200941110511091:CAS:528:DC%2BD1MXhtFaju73K10.1038/ng.449 – volume: 105 start-page: 7034 year: 2008 ident: BFgene201366_CR11 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0707882105 – volume: 56 start-page: 444 year: 2012 ident: BFgene201366_CR22 publication-title: Hepatology doi: 10.1002/hep.25647 – volume: 55 start-page: 384 year: 2012 ident: BFgene201366_CR38 publication-title: Hepatology doi: 10.1002/hep.24678 – volume: 140 start-page: 1021 year: 2011 ident: BFgene201366_CR12 publication-title: Gastroenterology doi: 10.1053/j.gastro.2010.11.039 – volume: 4 start-page: 63 year: 2003 ident: BFgene201366_CR8 publication-title: Nat Immunol doi: 10.1038/ni873 – volume: 40 start-page: 708 year: 2004 ident: BFgene201366_CR36 publication-title: Hepatology doi: 10.1002/hep.20371 – volume: 4 start-page: 69 year: 2003 ident: BFgene201366_CR7 publication-title: Nat Immunol doi: 10.1038/ni875 – volume: 314 start-page: 637 year: 1985 ident: BFgene201366_CR25 publication-title: Nature doi: 10.1038/314637a0 – volume: 7 start-page: e37998 year: 2012 ident: BFgene201366_CR37 publication-title: PloS One doi: 10.1371/journal.pone.0037998 – volume: 75 start-page: 53 year: 2000 ident: BFgene201366_CR43 publication-title: Biol Trace Elem Res doi: 10.1385/BTER:75:1-3:53 – volume: 56 start-page: 527 year: 2012 ident: BFgene201366_CR6 publication-title: J Hepatol doi: 10.1016/j.jhep.2011.09.008 – volume: 130 start-page: 1085 year: 2000 ident: BFgene201366_CR31 publication-title: J Nutr doi: 10.1093/jn/130.5.1085 – volume: 142 start-page: 1122 year: 2012 ident: BFgene201366_CR21 publication-title: Gastroenterology doi: 10.1053/j.gastro.2012.01.028 – volume: 33 start-page: 2568 year: 2012 ident: BFgene201366_CR33 publication-title: Carcinogenesis doi: 10.1093/carcin/bgs287 – volume: 10 start-page: 702 year: 2009 ident: BFgene201366_CR16 publication-title: Genes Immun doi: 10.1038/gene.2009.72 – volume: 29 start-page: 4778 year: 2009 ident: BFgene201366_CR17 publication-title: Mol Cell Biol doi: 10.1128/MCB.01808-08 – volume: 3 start-page: 57 year: 2011 ident: BFgene201366_CR18 publication-title: Genome Med doi: 10.1186/gm273 – volume: 19 start-page: 481 year: 2005 ident: BFgene201366_CR42 publication-title: Can J Gastroenterol doi: 10.1155/2005/262597 – volume: 57 start-page: 516 year: 2008 ident: BFgene201366_CR10 publication-title: Gut doi: 10.1136/gut.2007.128611 – volume: 139 start-page: 499 year: 2010 ident: BFgene201366_CR13 publication-title: Gastroenterology doi: 10.1053/j.gastro.2010.04.049 – volume: 11 start-page: R106 year: 2010 ident: BFgene201366_CR53 publication-title: Genome Biol doi: 10.1186/gb-2010-11-10-r106 – volume: 36 start-page: S21 year: 2002 ident: BFgene201366_CR2 publication-title: Hepatology doi: 10.1002/hep.1840360704 – volume: 41 start-page: 1100 year: 2009 ident: BFgene201366_CR4 publication-title: Nat Genet doi: 10.1038/ng.447 – volume: 19 start-page: 843 year: 2012 ident: BFgene201366_CR15 publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2012.01610.x – volume: 138 start-page: e1121 year: 2010 ident: BFgene201366_CR20 publication-title: Gastroenterology – volume: 55 start-page: 1700 year: 2012 ident: BFgene201366_CR19 publication-title: Hepatology doi: 10.1002/hep.25582 – ident: BFgene201366_CR52 – volume: 73 start-page: 4713 year: 1999 ident: BFgene201366_CR34 publication-title: J Virol doi: 10.1128/JVI.73.6.4713-4720.1999 – volume: 10 start-page: R25 year: 2009 ident: BFgene201366_CR51 publication-title: Genome Biol doi: 10.1186/gb-2009-10-3-r25 – volume: 110 start-page: 7802 year: 2013 ident: BFgene201366_CR30 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1211776110 – volume: 52 start-page: 1220A year: 2010 ident: BFgene201366_CR39 publication-title: Hepatology – volume: 20 start-page: 17 year: 2000 ident: BFgene201366_CR32 publication-title: Semin Liver Dis doi: 10.1055/s-2000-9505 – volume: 22 start-page: 1211 year: 2010 ident: BFgene201366_CR45 publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0b013e32833caf7b – volume: 6 start-page: 26 year: 1986 ident: BFgene201366_CR26 publication-title: Mol Cell Biol doi: 10.1128/MCB.6.1.26 – volume: 41 start-page: 1105 year: 2009 ident: BFgene201366_CR5 publication-title: Nat Genet doi: 10.1038/ng.449 – volume: 31 start-page: 656 year: 2000 ident: BFgene201366_CR35 publication-title: Hepatology doi: 10.1002/hep.510310316 – volume: 142 start-page: 229 year: 1997 ident: BFgene201366_CR49 publication-title: Toxicol Appl Pharmacol doi: 10.1006/taap.1996.8054 – volume: 10 start-page: 130 year: 2002 ident: BFgene201366_CR47 publication-title: Wound Repair Regen doi: 10.1046/j.1524-475X.2002.20101.x – volume: 44 start-page: 1 year: 2009 ident: BFgene201366_CR48 publication-title: Prog Histochem Cytochem doi: 10.1016/j.proghi.2008.10.002 – volume: 44 start-page: 287 year: 2012 ident: BFgene201366_CR29 publication-title: Drug Metab Rev doi: 10.3109/03602532.2012.725414 – volume: 131 start-page: 1887 year: 2006 ident: BFgene201366_CR9 publication-title: Gastroenterology doi: 10.1053/j.gastro.2006.09.052 – volume: 83 start-page: 3346 year: 1986 ident: BFgene201366_CR27 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.83.10.3346 – volume: 5 start-page: 41 year: 2012 ident: BFgene201366_CR28 publication-title: J Hematol Oncol doi: 10.1186/1756-8722-5-41 – volume: 97 start-page: 13631 year: 2000 ident: BFgene201366_CR40 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.250477397 – volume: 472 start-page: 481 year: 2011 ident: BFgene201366_CR50 publication-title: Nature doi: 10.1038/nature09907 – volume: 533 start-page: 201 year: 2003 ident: BFgene201366_CR24 publication-title: Mutat Res doi: 10.1016/j.mrfmmm.2003.07.013 – ident: BFgene201366_CR1 doi: 10.1053/gast.2002.1232082 – volume: 52 start-page: 1888 year: 2010 ident: BFgene201366_CR14 publication-title: Hepatology doi: 10.1002/hep.23912 – volume: 7 start-page: 761 year: 2007 ident: BFgene201366_CR46 publication-title: Mini Rev Med Chem doi: 10.2174/138955707781024490 – volume: 461 start-page: 798 year: 2009 ident: BFgene201366_CR23 publication-title: Nature doi: 10.1038/nature08463 – volume: 8 start-page: 367 year: 2001 ident: BFgene201366_CR44 publication-title: J Viral Hepat doi: 10.1046/j.1365-2893.2001.00311.x – volume: 461 start-page: 399 year: 2009 ident: BFgene201366_CR3 publication-title: Nature doi: 10.1038/nature08309 – volume: 98 start-page: 1142 year: 2003 ident: BFgene201366_CR41 publication-title: Am J Gastroenterol |
| SSID | ssj0016169 |
| Score | 2.1656337 |
| Snippet | The IFNL3 genotype predicts the clearance of hepatitis C virus (HCV), spontaneously and with interferon (IFN)-based therapy. The responder genotype is... |
| SourceID | proquest gale pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 88 |
| SubjectTerms | 631/250/127/1212 631/250/2502/248 692/699/255/234/2513/1551 692/700/565 Biomedical and Life Sciences Biomedicine Biopsy Cancer Research Chronic infection Fibrosis Gene Expression Genes Genetic aspects Genomes Genotype Genotype & phenotype Genotypes Hepacivirus Hepatitis C Hepatitis C virus Hepatitis C, Chronic - drug therapy Human Genetics Humans Immune clearance Immunology Infections Interferon Interferon alpha Interferon Regulatory Factors - genetics Interferon-alpha - therapeutic use Interferons Interleukins - genetics Liver Liver - pathology Liver - virology Liver Cirrhosis - genetics Metallothionein Metallothionein - biosynthesis original-article Peripheral blood Physiological aspects Polyethylene Glycols - therapeutic use Polymorphism, Single Nucleotide Recombinant Proteins - therapeutic use Ribavirin - therapeutic use Treatment Outcome Up-Regulation Viral Load - genetics |
| Title | Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent |
| URI | https://link.springer.com/article/10.1038/gene.2013.66 https://www.ncbi.nlm.nih.gov/pubmed/24335707 https://www.proquest.com/docview/1504529281 https://www.proquest.com/docview/2641736816 https://www.proquest.com/docview/1505256828 https://www.proquest.com/docview/1524419557 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgExIviG8KYzKIjwdkcGLHTp7QqFZ1CCo0mNQ3y3YcVgnSsaQI_nvuEqdbp7GXSI1PiXO2z7_zXX9HyAuZ-qL0MmEuU47JTHDmUl4ihWgp8BTDOnQUP8_U9Eh-nGfzeODWxLTKwSZ2hrpcejwjfwfABWOEaZ68P_nFsGoURldjCY3rZBupyzClS8_XDheAma6kHRgDxQCYFzHxnQtw-sCSYGKXeNvxI55tSRcN87md6UKotNuBJrfJrQgd6V4_1nfItVDfJTf6YpJ_75EwDZgd7enP0GI0vT1GEqJFTcOfmOxaU_jlezZcetxJt4uGjunvxemqoUNeFog19GAy-yQoMrjiIS0bauW298nRZP_beMpiEQXmAZy1zOXWKSeUrbwrvBReaZ5Y56zTRQXgK6ngahNZgqfqU9jdHc-85BLuVFWugnhAtmro7iNCARsFKzOrfcGlr1QRRGmDRkZ9QCVBj8ibQY_GR4ZxLHTxw3SRbpEb1LpBrRulRuTlWvqkZ9b4j9xzHBKDZBU1ZsN8t6umMQdfD80exlA1AFg-Iq-jULWEV3ob_1wAHUd-qw3JnQ1JWE1-s3kYeRNXc2PO5t6lzYApEy1UnkBfn62b8cGYwFaH5ap7RAboEvzbq2QAa8E0zkCTD_tJt9ZMKoXINIeWV8MsPNe_S9T2-OoPeUJugqDss-l2yFZ7ugpPAV61brdbQ3DNx8ku2f6wP_ty-A-JhSPU |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTgheEN8rDDCIwQMKS2LHaR4QGmNVy7oKjU3am7Edh1WCdCwpsH-Kv5G7fHTrNPa2l0qtr657Pt_9zne5A3gpQpukVgSeiaTxRMR9z4R-SiVEU063GNqQo7gzloN98ekgOliCv-2zMJRW2erESlGnU0t35OsIXChGGPaC90c_PeoaRdHVtoVGLRbb7uQ3umzFu-FH3N-1MOxv7W0OvKargGcRrZSe6WkjDZc6syaxglsZ-4E2Rps4yRCNBBm-6kCk6LrZEM2d8SMrfIGfZFlPOo7zXoNlwdGV6cDyh63x59153EIGVRM9VD_SQ1cgaVLtfY5uJuouSiXjb6uKjKdG8LwpOGMLzwVnK5vXvw23GrDKNmrpugNLLr8L1-v2lSf3wA0c5WNb9sOVFL8vD6ns0SRn7k-TXpszfGfr-rvssKIuJwXbZL8mx7OCtZlgSFawYX884oxqxtK1sNd25y3vw_6VMPgBdHJc7gowRGNOi0jHNvGFzWTieKpdTDX8EQe5uAtvWj4q29Q0p9Ya31UVW-c9RVxXxHUlZRfW5tRHdS2P_9C9oC1RVB4jp_ybb3pWFGr4ZVdtUNQ2Rsjsd-F1Q5RN8Setbh5nwIVTRa0FytUFSjy_dnG43XnV6I9CnUr7hcOIYoOYy16Aa30-H6aJKWUud9NZNUWEeBY96stoEN0FSRQhJx_WQjfnTCg4j2IfR161UnhmfRew7dHlf-QZ3Bjs7YzUaDjefgw38UuizuVbhU55PHNPENyV5mlzohh8vepD_A_IN2Bk |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGEIgXxOcoG2AQgweULYm_kgeEpo2qZaNCwKS-GdtxWCVIx5IO9q_x13GXj26dxt72Uqn11XXPd77f-S53hLzksUszx6PACmkDLlgY2DjMsIRoxvAWw1h0FD-O5GCffxiL8RL52z0Lg2mV3ZlYH9TZ1OEd-SYAF4wRxkm0mbdpEZ92-u8OfwXYQQojrV07jUZEdv3Jb3DfyrfDHdjr9Tjuv_-6PQjaDgOBA-RSBTYxVlomTe5s6jhzUoWRsdZYleaATKIcXk3EM3DjXAymz4bC8ZDDJ3meSM9g3mvkumIiQh1T47mzB0CqbqcHB5EMwClI26T7kIHDCacYJpWxjbo246k5PG8UzljFc2Ha2vr175DbLWylW42c3SVLvrhHbjSNLE_uEz_wmJnt6E9fYSS_OsACSJOC-j9tom1B4Z1rKvHSg5q6mpR0mx5PjmYl7XLCgKykw_5oj1GsHosXxEHXp7d6QPavhL0PyXIBy31EKOAyb7gwyqUhd7lMPcuMV1jNHxCRVz3ypuOjdm11c2yy8UPXUXaWaOS6Rq5rKXtkfU592FT1-A_dC9wSjYUyChS572ZWlnr45bPewvitAvAc9sjrliifwk860z7YAAvH2loLlGsLlKDJbnG423ndniSlPpX7C4cBz0aKySSCtT6fD-PEmDxX-OmsnkIAsgXf-jIawHlRKgRwcqURujlnYs6YUCGMvOqk8Mz6LmDb48v_yDNyE1RX7w1Hu6vkFnyHN0l9a2S5Opr5J4DyKvu0VidKvl21_v4DSL9jNA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hepatic+metallothionein+expression+in+chronic+hepatitis+C+virus+infection+is+IFNL3+genotype-dependent&rft.jtitle=Genes+and+immunity&rft.au=O%27Connor%2C+K+S&rft.au=Parnell%2C+G&rft.au=Patrick%2C+E&rft.au=Ahlenstiel%2C+G&rft.date=2014-03-01&rft.issn=1466-4879&rft.volume=15&rft.issue=2&rft.spage=88&rft.epage=94&rft_id=info:doi/10.1038%2Fgene.2013.66&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1466-4879&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1466-4879&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1466-4879&client=summon |